These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16644054)

  • 1. Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery.
    Gomes dos Santos AL; Bochot A; Doyle A; Tsapis N; Siepmann J; Siepmann F; Schmaler J; Besnard M; Behar-Cohen F; Fattal E
    J Control Release; 2006 May; 112(3):369-81. PubMed ID: 16644054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term release and improved intracellular penetration of oligonucleotide-polyethylenimine complexes entrapped in biodegradable microspheres.
    De Rosa G; Quaglia F; Bochot A; Ungaro F; Fattal E
    Biomacromolecules; 2003; 4(3):529-36. PubMed ID: 12741766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gel and solid matrix systems for the controlled delivery of drug carrier-associated nucleic acids.
    Fattal E; De Rosa G; Bochot A
    Int J Pharm; 2004 Jun; 277(1-2):25-30. PubMed ID: 15158966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain.
    Khan A; Sommer W; Fuxe K; Akhtar S
    J Drug Target; 2000; 8(5):319-34. PubMed ID: 11328659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells.
    Aukunuru JV; Ayalasomayajula SP; Kompella UB
    J Pharm Pharmacol; 2003 Sep; 55(9):1199-206. PubMed ID: 14604462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polyethylenimine but not cationic lipid improves antisense activity of 3'-capped phosphodiester oligonucleotides.
    Dheur S; Dias N; van Aerschot A; Herdewijn P; Bettinger T; Rémy JS; Hélène C; Saison-Behmoaras ET
    Antisense Nucleic Acid Drug Dev; 1999 Dec; 9(6):515-25. PubMed ID: 10645777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel antisense oligonucleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome.
    Cordeiro MF; Mead A; Ali RR; Alexander RA; Murray S; Chen C; York-Defalco C; Dean NM; Schultz GS; Khaw PT
    Gene Ther; 2003 Jan; 10(1):59-71. PubMed ID: 12525838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes.
    De Rosa G; Quaglia F; La Rotonda MI; Appel M; Alphandary H; Fattal E
    J Pharm Sci; 2002 Mar; 91(3):790-9. PubMed ID: 11920765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative three-dimensional analysis and diffusion modeling of oligonucleotide concentrations after direct intraparenchymal brain infusion.
    Haar PJ; Stewart JE; Gillies GT; Prabhu SS; Broaddus WC
    IEEE Trans Biomed Eng; 2001 May; 48(5):560-9. PubMed ID: 11341530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system.
    Wu D; Boado RJ; Pardridge WM
    J Pharmacol Exp Ther; 1996 Jan; 276(1):206-11. PubMed ID: 8558431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biodegradable chitosan scaffolds containing microspheres as carriers for controlled transforming growth factor-beta1 delivery for cartilage tissue engineering.
    Cai DZ; Zeng C; Quan DP; Bu LS; Wang K; Lu HD; Li XF
    Chin Med J (Engl); 2007 Feb; 120(3):197-203. PubMed ID: 17355821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human anti-transforming growth factor-beta2 antibody: a new glaucoma anti-scarring agent.
    Cordeiro MF; Gay JA; Khaw PT
    Invest Ophthalmol Vis Sci; 1999 Sep; 40(10):2225-34. PubMed ID: 10476787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyelectrolyte complex micelles composed of c-raf antisense oligodeoxynucleotide-poly(ethylene glycol) conjugate and poly(ethylenimine): effect of systemic administration on tumor growth.
    Jeong JH; Kim SH; Kim SW; Park TG
    Bioconjug Chem; 2005; 16(4):1034-7. PubMed ID: 16029047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition.
    Mok H; Park JW; Park TG
    Bioconjug Chem; 2007; 18(5):1483-9. PubMed ID: 17602578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes.
    De Rosa G; Bochot A; Quaglia F; Besnard M; Fattal E
    Int J Pharm; 2003 Mar; 254(1):89-93. PubMed ID: 12615416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
    Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
    Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.
    Hau P; Jachimczak P; Bogdahn U
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1663-74. PubMed ID: 19895249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.
    Schlingensiepen R; Goldbrunner M; Szyrach MN; Stauder G; Jachimczak P; Bogdahn U; Schulmeyer F; Hau P; Schlingensiepen KH
    Oligonucleotides; 2005; 15(2):94-104. PubMed ID: 15989424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodegradable microparticles for the controlled delivery of oligonucleotides.
    De Rosa G; Quaglia F; La Rotonda M; Besnard M; Fattal E
    Int J Pharm; 2002 Aug; 242(1-2):225-8. PubMed ID: 12176251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver.
    Robaczewska M; Guerret S; Remy JS; Chemin I; Offensperger WB; Chevallier M; Behr JP; Podhajska AJ; Blum HE; Trepo C; Cova L
    Gene Ther; 2001 Jun; 8(11):874-81. PubMed ID: 11423935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.